PaxMedica (PaxMedica) Buyback Yield % : -223.80 (As of Jun. 04, 2024)

View and export this data going back to 2022. Start your Free Trial

What is PaxMedica Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

PaxMedica's current buyback yield was -223.80%.

PaxMedica Buyback Yield % Historical Data

The historical data trend for PaxMedica's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PaxMedica Buyback Yield % Chart

PaxMedica Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buyback Yield %

Get a 7-Day Free Trial

-24.51

-209.72

PaxMedica Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Buyback Yield %	Get a 7-Day Free Trial															-90.34	47.35	-60.89	-455.49	-

Competitive Comparison of PaxMedica's Buyback Yield %

For the Biotechnology subindustry, PaxMedica's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PaxMedica's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PaxMedica's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where PaxMedica's Buyback Yield % falls into.

PaxMedica Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

PaxMedica's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (-0.196	+	11.946)	/	5.60273868
	=	-209.72%

PaxMedica's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	3.8074713
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.

PaxMedica Buyback Yield % Related Terms

Thank you for viewing the detailed overview of PaxMedica's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

PaxMedica (PaxMedica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PaxMedica Inc (OTCPK:PXMD) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591

Website

https://www.paxmedica.com

PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.

Executives

Zachary Rome	director, officer: Chief Operating Officer	C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Michael Derby	director, officer: Executive Chairman	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Howard J. Weisman	director, officer: Chief Executive Officer	C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Karen Larochelle	director	900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
John F Coelho	director	22 BENEDICT CRESCENT, BASKING RIDGE NJ 07920
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
David W. Hough	officer: Chief Medical Officer	C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Tardimed Sciences Llc	10 percent owner	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Stephen Sheldon	officer: Chief Financial Officer	2 REVOLUTIONARY WAY, #312, HOPKINTON MA 01748